**Genomics Segment (Diagnostics): Tempus AI's Genomics generates revenue through next-generation sequencing (NGS) tests billed to physicians and payors upon result delivery, with reimbursement net of allowances based on historical collections (e.g., Medicare ADLT rates), creating a volume-driven flywheel where higher test volumes feed proprietary data into the AI platform—ASP improvements from FDA approvals like xT CDx migrate tests from ~$2,900 LDT to $4,500 reimbursed rates, boosting margins from 46% in FY2024 to 60% in FY2025 while organic volume grew 30% excluding Ambry acquisition.[1][2]
- FY2025 revenue: $955.4 million (111.5% YoY growth); Q4 2025: $266.9 million (121.6% YoY).[1]
- Oncology (Tempus core): $139.5 million in Q3 2025 (31.7% YoY, 27% volume growth to ~87,500 NGS tests); Hereditary (Ambry): $102.6 million in Q3 (32.8% pro forma YoY, 37% volume); FY Oncology ASP: $1,510 (up from $1,450 in 2024).[3]
- Key products: xT CDx (648-gene solid tumor NGS, FDA-approved, $4,500 ASP); xF (105-gene liquid biopsy, $3,288 CMS rate); xR (RNA, 510(k)-cleared); xM MRD (4,700 tests Q4, 56% QoQ); ~30% xT volume migrated to CDx in Q3 2025.[1]
- Gross margins: FY2025 59.6% (non-GAAP 60.3%), driven by reimbursement tailwinds (e.g., xT CDx >$500 ASP uplift expected).
For competitors like Guardant or Natera entering, Tempus's integrated data moat (8M+ de-identified records) enables multimodal algos bundled free with tests, locking in 87% physician retention for high-volume users—new entrants lack this scale, facing 40-50% gross margins without AI differentiation.[4]

**Data & Services / AI Segment: Tempus monetizes its multimodal dataset (clinical/molecular/imaging from Genomics) via multi-year subscriptions and one-time licenses to biopharma, recognized ratably over access periods or upon delivery, with 126% NRR from expansions like the $200M AstraZeneca/Pathos foundation model deal—Insights dominates as low marginal cost (data already generated), yielding 73% margins vs. Genomics' 60%, while AI apps scale via EHR integration without heavy sales spend.[1][4]
- FY2025 revenue: $316.4 million (30.9% YoY); Q4: $100.4 million (25.1% YoY); Insights: 38% YoY growth, Q4 69.5% (ex-AZ warrant); TCV >$1.1B (up from $940M end-2024), $2B+ contracts signed.[2]
- Sub-breakdown (2024 for reference, similar FY2025 structure): Insights ~77% ($186.8M), Trials/TIME ~17% ($42.4M), AI/Algos ~5% ($12.4M); Q3 2025 Insights $69M (implied ~85%), TIME $9.2M (~11%).[4][5]
- Key products: Lens platform (data access/AI tools); >8M records delivered; partnerships (19/20 top pharmas).
For data rivals like Flatiron or ConcertAI, Tempus's real-time Genomics linkage (e.g., 270k+ annual oncology tests) enables unique multi-omics RWD for AI training—licensing at 140% NRR creates a moat where scale begets better models, pricing out smaller datasets.[1]

**Emerging Insights Division: Referred to as the data licensing powerhouse within Data & Services, Insights licenses de-identified multimodal libraries (clinical/molecular/imaging) plus analytics/cloud tools to biopharma for drug discovery/target ID, with revenue from subscriptions (ratable) or one-offs (upon delivery)—growth accelerates via network effects, as Genomics volumes expand the dataset, hitting 38% YoY in FY2025 amid $150M+ quarterly bookings, non-obviously turning fixed lab costs into recurring high-margin (~75%) revenue with minimal incremental COGS.[1]
- FY2025: ~$250M+ implied (78%+ of Data segment, based on 2024 split and growth); drove 37.6% of Data Q3 growth; NRR 126%; examples: $66M/4yr biotech, $45M study collab.[3]
- Economics: Multi-year deals (e.g., AZ $200M/3yr); TCV expansion outpaces revenue; gross margin 73.3% non-GAAP FY2025.
Entrants must bootstrap datasets without Tempus's 7,500+ oncologist network—Insights' 126% NRR implies pricing power from exclusivity, where competitors face commoditized data at lower retention.[1]

**Overall Revenue Model & Growth Drivers: Tempus' flywheel links Genomics (75% FY2025 mix, volume/reimbursement-led) to Data/AI (25%, high-margin recurring), where tests generate proprietary data fueling Insights licensing and TIME/Algos—FY2025 total $1.3B (83% YoY, 30% organic ex-Ambry), gross profit $798M (109% YoY), Adj. EBITDA -$7M (near breakeven); 2026 guide $1.59B (25% growth), $65M EBITDA, as ASPs rise (Oncology >$2,200 path) and Data TCV converts.[2]
- Q1-Q3 2025 Genomics: $688.5M; Data: $216M; TIME Q3: $9.2M.[5]
- Drivers: FDA clearances (xF/xR PMA pending), MRD reimbursement, pharmas (GSK/Pfizer), 29% oncology volume.
To compete, focus on niche data (e.g., rare diseases) or partnerships—Tempus's end-to-end moat (lab-to-AI) yields 65%+ blended margins at scale, vs. pure-play diagnostics' 50% cap.[1]

**Key Products & Pricing Economics: xT CDx solidifies Genomics leadership via FDA reimbursement premium ($4,500 vs. LDT $2,900), enabling 30% volume migration and >$500 ASP uplift; xF liquid biopsy pairs with tissue for 9% unique ctDNA findings; TIME matches 40k+ patients via AI on real-time data, revenue on enrollment (~$9M Q3); bundled Algos (HRD/TO, >123k ordered) drive upsell without separate billing yet.[1][4]
- Pricing: Oncology NGS ASP $1,510 FY2025; Hereditary $790; ECG-AF $128 CPT; Data licenses multi-year (e.g., $200M/3yr).
New products face reimbursement hurdles (1-2yr delays)—Tempus accelerates via PMA/ADLT, turning regulatory wins into 20%+ ASP growth non-obviously.[1]

**Confidence & Gaps: High confidence in FY2025 figures from earnings releases/decks (verified across Qs); medium on sub-Data splits (2024 detailed in 10-K, 2025 proportional); AI/Insights/TIME estimates derived (low-single-digit % total for AI). Additional 10-K (post-Feb 2026) would confirm FY2025 breakdowns; no material discrepancies vs. training data.[4]

Recent Findings Supplement (March 2026)

Genomics Segment (Next-Generation Sequencing, Liquid Biopsy, Genetic Testing)

Tempus AI's Genomics—now rebranded Diagnostics in recent reporting—powers its flywheel by running high-volume tests like xT CDx (648-gene tumor profiling) and xF liquid biopsy, generating proprietary multimodal data that feeds the higher-margin Data business; in Q4 2025, oncology volumes surged 29% YoY to 340,500 tests at an ASP of ~$1,640 (up $40 QoQ), with ~$200 uplift expected from full xT CDx FDA migration by end-2026 (LDT $2,900 to CDx $4,500), plus $230 from xF clearance and $150+ from coverage expansions targeting >$2,200 ASP.[1][2][3]
• Q4 2025 revenue: $266.9M (+121.6% YoY); FY2025: $955.4M (+111.5% YoY), with oncology +26% and hereditary +29% volumes (125,000 tests, ASP $800); MRD tests hit 4,700 (+56% QoQ).[4][3]
• Non-GAAP gross margin: 62.2% in Q4 (up from 49.6% YoY), reflecting scale and mix shift to higher-ASP tests post-Ambry acquisition.[2]
For competitors entering genomics, Tempus' data flywheel creates a moat—replicating 450+ petabytes of linked clinical/molecular data is infeasible without equivalent testing scale, making pure-play sequencers vulnerable on pricing (~30-40% margins vs. Tempus' 60%+).

Data & Services / AI Segment (Dataset Licensing, AI Apps to Pharma/Hospitals)

Tempus monetizes its de-identified dataset (8M+ records, 400+ petabytes) via Insights licensing to 19/20 top pharmas (e.g., AZ $200M/3yrs, GSK $70M/3yrs), where AI tools like Lens platform and foundation models enable drug discovery/trial design; Q4 2025 Insights revenue jumped 69.5% YoY (ex-prior AZ warrant), backed by >$1.1B TCV and 126% NRR, with multi-year deals converting steadily (Q4 historically strongest).[3][5]
• Q4 2025 revenue: $100.4M (+25.1% YoY); FY2025: $316.4M (+30.9% YoY), ~24% of total (up from prior years).[3]
• Non-GAAP gross margin: 74.5% Q4 (software-like, down slightly YoY from foundation model compute); includes apps like TIME (trial matching) and Next (care gaps).[1]
New entrants face near-insurmountable data barriers—Tempus' longitudinal multimodal library (genomics + imaging + clinical) yields 37-69% Insights growth, while rivals lack the "sensor" (testing volume) to build comparable assets.

Emerging Insights Division (High-Margin Data Licensing Core)

Insights has accelerated as Tempus' crown jewel within Data & Services, licensing AI-curated datasets for pharma R&D (e.g., Recursion, Pathos); FY2025 growth hit 38% on $150M Q3 bookings alone (+multi-year Lens expansions, $45M study collab), with TCV ballooning to >$1.1B by YE2025—visibility implies 40%+ Q1 2026 growth, subsidizing diagnostics via 70%+ margins.[4][6]
• Explicitly called out as "having a moment," comprising bulk of Data revenue; NRR 126% signals sticky multi-year pharmas expanding usage.[5]
• Paige Predict launch (Jan 2026) adds AI pathology (123 biomarkers/16 cancers from H&E slides), enhancing dataset for future licensing.[2]
To compete, others must aggregate equivalent data at scale—Tempus' 5,500+ hospital links and 7.5M+ slides (post-Paige) lock in pharmas, turning commoditized data into defensible AI moat.

Q4/FY2025 Financial Snapshot & Regulatory Catalysts

Tempus hit FY2025 total revenue of $1.3B (+83.4% YoY, beating $1.265B guide), with Q4 $367.2M (+83% YoY, organic 33.5% ex-Ambry); Adjusted EBITDA turned positive at $12.9M Q4 / ($7.4M) FY (post-acquisitions). xF liquid biopsy FDA submitted (minimal 2026 ASP impact, ramps 2027); xT CDx at 30%+ volume, majority by end-2026 for reimbursement uplift; xR 510(k) cleared Q3.[3][1]
• 2026 guide: $1.59B revenue (+25%), $65M Adj. EBITDA—sustains diagnostics volumes + data pull-forward.[3]
Rivals chasing regulatory parity (e.g., FDA PMA/NCD) face Tempus' first-mover scale; without it, ASP stays capped at LDT levels.

Growth Economics & Competitive Implications

Tempus' segments interlock—Genomics volumes (217k Q3 tests, 33% YoY) fuel Data flywheel, yielding 73%+ margins vs. Genomics' 60%; FY2025 gross profit $797.9M (+109%), cash $759.7M supports AI compute/regulatory pushes (e.g., foundation models Q1 2026). No major policy changes noted, but ARPA-H CRO award (Oct 2025) boosts hereditary.[3]
• Confidence: High on figures (direct from releases/transcripts); estimates consistent across sources (e.g., $1.27-1.3B FY total).
New players must bootstrap data via loss-leader testing—Tempus' $2B+ Data contracts and 25% 2026 guide (post-83% ramp) signal maturing economics, pressuring incumbents without AI/data integration.

Dataset Scale and Multimodality

Tempus AI leverages its proprietary OS platform to aggregate multimodal data from over 5,000 U.S. healthcare sites via 700+ connections, creating a de-identified library exceeding 450 petabytes that links real-time clinical EHR notes (1.6B+ pages), genomics (4M+ sequenced samples), imaging (8M+ records), and transcriptomics (350K+ profiles) for 8.5M+ research records—90x larger than TCGA—enabling AI models to predict outcomes like immunotherapy response via signatures like Immune Profile Score (IPS), which outperforms PD-L1 alone by integrating histopathology and genomics.[1][2]
- 45M+ total patient records; 55% U.S. oncologist reach; 65% academic centers; used in 1,500+ research projects[2]
- Powers Tempus Lens for cohort building/matching; agentic AI extracts unstructured text into structured data for longitudinal tracking[3]

Implications for Competitors: Tempus' near-real-time, EHR-linked multimodality creates a "living" dataset for dynamic AI training, unlike static snapshots from rivals.

Competition Barriers: New entrants need 5-10 years and $500M+ to match scale; pharma must integrate Tempus' data moat or risk suboptimal models.

Reimbursement Status of Flagship Assays

Tempus' xT CDx (648-gene solid tumor NGS) gained FDA approval and CMS ADLT status at $4,500 (vs. LDT ~$2,900), with Q4 2025 oncology ASP $1,640 (rising to >$2,200 via xF liquid biopsy PMA submission and xR RNA); xF1 (liquid) pending full NCD 90.2 coverage; Medicare covers qualifying advanced solid tumors, driving 26% oncology volume growth.[2]
- Commercial in-network with Cigna/Humana/BCBS; hereditary ASP ~$800[2]

Implications: Rivals like Foundation/Guardant hold mature pan-tumor NCDs; Tempus catching up via CDx migration (30% xT vol.).

Competition Barriers: FDA/CMS pathways demand clinical utility data; Tempus' volume accelerates parity by 2026.

Pharma Partnership Deal Volume and Values

Tempus signed 70+ data deals in 2025 with 19/20 top pharma (AstraZeneca/Pathos foundation model; Merck AI; Pfizer/GSK/BMS/Novartis), yielding >$1.1B TCV (126% NRR), $316M data rev (31% growth)—monetizing multimodal RWE for trial design/biomarkers via Lens AI.[2][8]
- 250+ biotechs; $2B+ contracts signed[2]

Implications: Tempus leads new deal velocity via AI-accessible data; Roche's legacy acquisitions (Foundation $2.4B '18, Flatiron $1.9B '18) provide internal moats but less external revenue.[9][10]

Competition Barriers: Guardant ($210M biopharma rev, Merck collab)[5]; Flatiron internal; Illumina alliances (AstraZeneca/Merck/Lilly Billion Cell Atlas)[11]; scale needs proprietary data+AI.

Clinical Workflow Integration

Tempus One (GenAI assistant) embeds in EHRs (e.g., Epic/Flatiron OncoEMR), querying patient data/guidelines (ASCO-integrated), auto-matching trials (TIME screened 245K pts), surfacing care gaps (NEXT)—reducing admin via agentic workflows across 5K sites/55% oncologists.[12][2]
- Orders/results flow bidirectionally; 123K+ Algos ordered[2]

Implications: Tempus' OS turns EHRs into AI hubs, unlike assay-focused rivals.

Competition Barriers: Flatiron OncoEMR leads EHR but lacks Tempus' genomic depth; Guardant/Foundation diagnostics integrate less seamlessly.

AI/ML Capabilities

Tempus' agentic AI platform (Tempus One/Lens) fine-tunes foundation models on proprietary 450PB multimodal data for IPS (immunotherapy), PurIST (PDAC subtyping), ECG-AFib (FDA-cleared), pathology viability prediction—powering 60+ algos, trial matching, outcome forecasting.[2]
- Collaborations: AstraZeneca/Pathos largest oncology foundation model[2]

Implications: Tempus' data moat yields superior models (e.g., IPS > PD-L1); Guardant/Illumina focus ML on assays; Roche/Flatiron lag agentic scale.

Competition Barriers: Tempus wins on data+AI flywheel; rivals lead reimbursement/integration—new entrants face insurmountable scale.

Recent Findings Supplement (March 2026)

Dataset Scale and Multimodality

Tempus AI solidified its data moat in late 2025 by announcing a record Total Remaining Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025, driven by 70+ new data licensing deals with pharma giants like AstraZeneca, Pfizer, GSK, and Merck; this TCV assumes full exercise of options and reflects committed future revenue from its multimodal library (>45M patient records, >8M imaging records, >4M sequenced samples, >350K DNA+RNA profiles), enabling AI training that outpaces rivals' siloed datasets.[1][2][3]
- Tempus ended 2025 with 126% net revenue retention in data licensing, signaling sticky pharma demand for its de-identified clinical+molecular+imaging data.
- Flatiron Health (Roche) launched AI-powered global prostate cancer datasets (Feb 2026) and 6 hematology datasets (Oct 2025) with 505K patients, plus ConcertAI integration for ~500K linked patients (Jan 2026), emphasizing clinical RWD over Tempus' genomics depth.[4][5]
- Guardant launched Single Namespace Group (Nov 2025) for exabyte-scale genomic data interoperability with NetApp, IBM, Genentech; no specific size update.[6]

Implications for Competitors: Tempus' TCV provides revenue visibility into 2026+ (~$350M committed for 2026), but rivals like Flatiron leverage Roche's ecosystem for clinical depth; new entrants need pharma tie-ups to match Tempus' scale, while Guardant/Illumina focus on tools enables lab decentralization.

Reimbursement Status of Flagship Assays

Illumina secured CMS reimbursement for its FDA-approved TruSight Oncology Comprehensive (TSO Comprehensive) at $2,989.55/test effective Jan 1, 2026 (PLA code 0543U), unlocking Medicare access for comprehensive genomic profiling (CGP) in advanced cancer and enabling in-house lab adoption beyond centralized testing.[7][8]
- Tempus received FDA 510(k) for Tempus xR IVD RNA NGS assay (Sep 2025); plans xF liquid biopsy FDA submission Q4 2025 and xR PMA; no new reimbursement noted.[9][10]
- Guardant360 CDx gained FDA CDx approval for BRAF V600E mCRC with Pfizer's Braftovi (Jan 2026); Shield blood test added to NCCN guidelines, with Medicare/TRICARE coverage.[11][12]
- Foundation Medicine hit 100 CDx indications (Dec 2025; 57 US, 43 Japan); no new reimbursement specifics.[13]

Implications for Competitors: Illumina's reimbursement structurally advantages decentralized CGP (e.g., community labs), pressuring Tempus/Guardant/FMI centralized models; Tempus must prioritize FDA/CMS for xF/xR to compete, as Guardant/FMI lead in CDx breadth.

Pharma Partnership Deal Volume and Values

Tempus expanded Merck multi-year deal (Mar 3, 2026) for AI biomarker discovery using de-identified multimodal data/Lens platform, building on prior ties; part of 70+ 2025 deals contributing to >$1.1B TCV (no per-deal values disclosed).[14][15]
- Guardant inked multi-year Merck deal (Jan 2026) for CDx development using Infinity platform; acquired MetaSight for up to $150M (Feb 2026) for early detection.[16][17]
- Foundation/Flatiron: Manifold AI partnership (Oct 2025) for FoundationInsights; ConcertAI data integration (Jan 2026).
- No new high-value deals for Illumina/Flatiron.

Implications for Competitors: Tempus leads volume (70+ deals, $1.1B TCV), differentiating via AI-multimodal access; Guardant matches on Merck but focuses CDx; Roche entities gain from integrations, but Tempus' TCV signals higher monetization—rivals need AI-data combos to compete.

Clinical Workflow Integration

Tempus integrated Median's FDA-cleared eyonis LCS AI lung screening into Pixel platform (Feb 2026), targeting 14.5M eligible US patients with existing reimbursement pathway ($601-700); launched Paige Predict AI pathology (Jan 2026) for 123 biomarkers/16 cancers from H&E slides.[18][19]
- Guardant/Quest multi-year deal for Shield CRC screening via Quest network (Q1 2026 rollout); Trial Library AI for trial matching (Dec 2025).[20]
- Flatiron sold clinical research business to Paradigm (Dec 2025) for OncoEMR integration.

Implications for Competitors: Tempus' Pixel/Paige embeds AI into radiology/pathology workflows, a moat vs. Guardant's screening focus; entrants must partner for EMR/radiology hooks, as Roche/Illumina lag in end-to-end integration.

AI/ML Capabilities

Tempus launched HRD-RNA algorithm (Feb 2026) for ovarian/HRD detection and Paige Predict (Jan 2026; >200K patient foundation model); Merck deal leverages GPU-powered Lens for AI training.[21]
- Flatiron debuted LLM-powered global datasets (prostate Feb 2026, hematology Oct 2025).
- Guardant/Zephyr AI for drug response predictions (Oct 2025); Single Namespace for AI data (Nov 2025).
- Foundation/Manifold AI for FoundationInsights (Oct 2025).

Implications for Competitors: Tempus differentiates with agentic AI on massive multimodal data (e.g., HRD-RNA auto-prediction), but Guardant/Flatiron close gap in RWD-AI; Illumina's multiomics (spatial/proteomics Feb 2026) enables tools play—competitors without proprietary data risk commoditization.[22]

Tempus Advantages: Unmatched TCV/deal volume, multimodal AI (Paige/HRD), workflow (Pixel).
Rivals' Structural Edges: Roche (FMI+Flatiron CDx/RWD scale), Guardant (liquid biopsy CDx leadership), Illumina (decentralized reimbursement/tools). Tempus must convert TCV to profitability (2026 EBITDA $65M guide) amid lawsuits (Guardant patents, data privacy). Confidence: High on announcements (primary sources); medium on dataset comparisons (no direct benchmarks). Additional 10-Ks strengthen quant rigor.

Revenue Growth Trajectory

Tempus AI's revenue accelerated dramatically from 2022 to 2025, driven initially by genomics scale-up and data licensing expansion, then supercharged by 2025 acquisitions like Ambry Genetics (hereditary testing), which boosted diagnostics to over 75% of mix while data/services provided high-margin stability; this flywheel—where diagnostics generate proprietary multimodal data fueling 38% Insights growth—created a structural shift, with total revenue compounding at ~59% CAGR over four years, though growth is expected to normalize to 25% in 2026 as comps toughen and organic diagnostics volumes (26-29%) sustain via reimbursement wins (oncology ASP up to $1,640 in Q4 2025, targeting >$2,200).[1][2][3]
- 2022: $320.7M total (62% genomics, 38% data/services)[1]
- 2023: $531.8M (+65.8% YoY; genomics +83%, data +38%)[1]
- 2024: $693.4M (+30.4%; genomics +24%, data +43%)[4]
- 2025: $1,271.8M (+83.4%; diagnostics/genomics $955.4M/+111%, data/apps $316.4M/+31%)[2]
- 2026 Guide: ~$1.59B (+25%), matching/slightly exceeding consensus ~$1.58B[5]

For competitors/new entrants, Tempus's data moat (>$1.1B TRCV, 126% NRR) locks in pharma deals (e.g., AstraZeneca), making replication hard without equivalent scale/volume for longitudinal RWD.[3]

Gross Margins by Segment (Genomics/Diagnostics vs. Data & Services)

Tempus's margins expanded via genomics lab efficiencies (automation, volume leverage) and data/services' software-like economics (73%+ non-GAAP), with mix shift pushing consolidated from 41% (2022) to 63% non-GAAP (2025); genomics margins tripled as fixed lab costs diluted over 26-29% volume growth, while data's near-zero marginal COGS (licensing de-identified datasets) sustained 70-80%, enabling operating leverage as data hit 25% mix.[1][4][3]

Non-GAAP margins ~3-5pts higher (excl. SBC). Wall Street expects continued expansion to 65-70% consolidated as data nears 35-40% mix.[6]

Entrants must match this leverage; pure-play diagnostics lack data flywheel for 70%+ services margins.

Operating Losses & Adjusted EBITDA Path

Operating losses narrowed as gross profit outpaced opex (despite acquisitions/SBC), with adj. EBITDA inflecting positive Q4 2025 ($12.9M) after steady improvement; mechanism: ~2/3 incremental gross profit reinvested, 1/3 to EBITDA, yielding $97M YoY gain despite Paige/OneOme costs—signals scale where revenue growth covers fixed opex.[2][3]

Consensus sees 2026 EBITDA ~$65M (company guide, aligns with ~$1.58-1.59B rev), margin ~4%—inflection via leverage.[5]

Milestone: Sustained quarterly positive EBITDA (achieved Q3-Q4 2025) signals profitability path; rivals need similar cost discipline.

Cash Burn Rate & Liquidity

Burn peaked 2023 amid investments but stabilized 2025 despite acquisitions, funded by $884M financing (notes/ATM); net ops cash use improved via working capital/gross profit, with $760M cash runway >3yrs at 2025 burn (~$218M ops). Mechanism: Receivables lag offset by data deferred rev; post-IPO/raises, liquidity buffers growth.[2][1]

For entrants, Tempus's $760M war chest funds M&A/AI without dilution soon; burn reduction via EBITDA key watch.

Wall Street Consensus & Profitability Milestones

Consensus aligns with guide (~$1.59B 2026 rev, $65M EBITDA), viewing Q4 positive EBITDA/margin gains as inflection; non-obvious: 126% NRR/$1.1B TRCV imply backlog conversion drives FCF by 2028-29, with ASP hikes/MRD scale as catalysts. Milestones: Q1 2026 EBITDA beat (guide ~$(5)M), oncology ASP >$2,000, data >35% mix—triggering sustained profitability.[5][3]

Compete by proving flywheel (volume→data→revenue); milestones validate defensibility. Data confidence high (SEC/earnings direct); 2022 estimates from S-1 (audited).

Recent Findings Supplement (March 2026)

Tempus AI's Q4/FY 2025 Earnings (Released Feb 24, 2026) Marked Its First Positive Adjusted EBITDA Quarter at $12.9M, Driven by 33.5% Organic Revenue Growth Excluding Ambry Acquisition—Signaling Margin Expansion via Scale in High-Margin Data Licensing (69% Insights Growth) While Genomics Volumes Surged 29% in Oncology.[1]
- FY 2025 revenue hit $1.3B (83.4% YoY), with Diagnostics/Genomics at $955.4M (111.5% YoY, Oncology +26%, Hereditary +29% volumes); Data & Services $316.4M (30.9% YoY, Insights +38%).[1]
- Gross margins: Diagnostics GAAP 59.6% (non-GAAP 60.3%), Data GAAP 72.3% (non-GAAP 73.3%), total GAAP 62.7%—up from prior periods due to pricing and mix shift.[1]
- Operating loss $252.9M FY; net loss $245.0M; FY Adjusted EBITDA $(7.4)M (improved $97M YoY despite Paige/OneOme costs); cash/marketables $759.7M end-2025 (no explicit burn rate, but prior Q3 op. cash use $181M nine months).[1][2]
For competitors/entering firms: Tempus' $1.1B+ remaining contract value and 126% NRR create a data moat; new entrants need proprietary multimodal datasets (450PB+) to replicate Insights scalability.

Q3 2025 10-Q (Filed Nov 4, 2025) Confirmed Genomics Margin Inflection to 61.0% GAAP on 117% Revenue Surge, While Data/Services Held 68.5%—Updating FY Guidance to $1.265B Revenue and Positive Adjusted EBITDA, a $100M+ YoY Improvement.[2][3]
- Q3 revenue $334.2M (+84.7% YoY); Genomics $252.9M (Oncology $139.5M +31.7%, Hereditary $102.6M +32.8% pro forma); Data/Services $81.3M (+26.1%, Insights +37.6%). Non-GAAP margins: Genomics 61.7%, Data 69.7%, total 63.6%.[2]
- Op. loss $61.0M Q3; net loss $80.0M; Adj. EBITDA +$1.5M (first positive); cash ~$656-764M; nine-mo. op. cash use $181M.[2]
- Guidance raised: FY2025 revenue ~$1.265B (~80% YoY), Adj. EBITDA slightly positive.[3]
Implication for rivals: Tempus' connected network (5K+ providers) enables rapid data augmentation/studies at low cost, barring replication without equivalent clinician integration.

Wall Street Consensus Eyes 2026 Revenue ~$1.59B and EBITDA Inflection at +$65M (Company Guide), with Profitability Path Hinging on MRD Adoption, AI Tools (e.g., Paige Predict Launch Jan 2026), and Reimbursement—Moderate Buy Rating ($79 PT Avg.).[4][1]
- Analysts (8 Buy/4 Hold/1 Sell): Guidance aligns but "muted" vs. 80%+ prior growth; EBITDA beats signal scale, but GAAP losses/debt persist.[4]
- Milestones: Q4 MRD tests +56% QoQ; $1.1B contract value; Immune Profile Score study; NYU/Northwestern collabs.[1]
For entrants: Path requires FDA clearances (e.g., HRD-RNA), pharma deals, and 25%+ sustained growth; Tempus' network effects barrier high. Confidence: High on reported data (SEC/PR); med on consensus (limited post-earnings detail). No Q1 2026 yet (exp. May).[6]

**Tempus AI trades at a forward EV/Revenue multiple of approximately 6.2x on 2026 revenue guidance of $1.59 billion, a discount to direct genomics peer Guardant Health's 12.7x TTM but aligned with the broader biotech/genomics sector median of 6.2x, because Tempus leverages its massive proprietary dataset (7+ million de-identified records) to auto-generate AI-driven insights for pharma partners like AstraZeneca, creating a flywheel where data volume directly fuels higher-margin Data & Services revenue (currently 25% of total, growing 31% YoY).[1][2][3]
- TTM revenue $1.27B (up 83% YoY), with Diagnostics (75% of mix) up 112% to $955M and Data/Services up 31% to $316M[1]
- Current EV $9.91B implies ~6.2x 2026 revenue; Finbox shows 8.8x forward today but compresses to 6.0x average over 5 years[4]
- Gross margins ~63% (gross profit $798M TTM), with Adjusted EBITDA guidance turning +$65M in 2026[5]

This positions Tempus for entrants seeking a data moat play: compete by partnering early on data licensing (e.g., Recursion-style deals) rather than building sequencing labs, but execution risk remains high if pharma R&D budgets tighten.

**Tempus AI's trailing P/S of 7.2x sits mid-pack versus peers like Veeva (10.6x, profitable SaaS leader) and Guardant (11.7x, blood-test focus), but premiums over software-like Schrodinger (3.7x) and hardware peers like 10x Genomics (4.0x) reflect Tempus' hybrid model—where AI matches patients to trials 3x faster via NLP on unstructured notes, driving 126% net revenue retention from existing pharma clients.[1][6][2][7][8]
- Market cap ~$9.3B; shares outstanding 174M at $52.26/share[1]
- Peers: RXRX ~20.8x-25x P/S (revenue ~$75M TTM, speculative AI-drug discovery); TXG 4.0x (revenue $643M)[9][8]
- Forward compression to ~5.8x P/S on $1.59B 2026 revenue guidance[10]

New competitors should target Veeva-like SaaS margins (target 80%+ gross) via AI analytics overlays, avoiding capex-heavy genomics; Tempus' P/B of 19x signals balance sheet strain from ongoing losses (-$245M net TTM), so focus on cash-efficient data plays.[1]

**Tempus AI's implied EV/Gross Profit multiple of ~12.4x (EV $9.91B / TTM gross profit $798M) mirrors high-growth diagnostics peers like Guardant while discounting pure software like Veeva, as its mechanism converts raw sequencing (low-margin) into AI-enriched datasets sold at 38% YoY growth in Insights licensing, with gross margins expanding from diagnostics scale (Q4 gross profit +95% YoY).[1][5]
- Gross profit $798M TTM (63% margin); peers: TXG ~$444M gross on $643M rev (69% margin, EV/GP ~5x); SDGR est. ~60-70% margins[8]
- No direct EV/GP consensus, but sector medians hover 10-15x for 50%+ growers (data estimated Q1 2026)[3]

For margin-focused entrants, justify premium via >70% gross margins early (emulate Veeva), as Tempus' current 63% leaves room for efficiency but risks commoditization in sequencing.

**Analysts price Tempus at consensus $78 (range $59-$100, Moderate Buy from 13-17 analysts), implying 49% upside from $52, with bull cases hinging on 25%+ 2026 revenue growth to $1.94B by 2027 and EBITDA positivity; bears cite persistent GAAP losses (-$0.06 EPS est. 2027) and high P/S premium if growth slows below 20%.[11][12][13]
- Recent: Morgan Stanley $70 (Overweight), Needham $75 (Buy from $100), Mizuho $100 (Outperform); 8 Buy/4 Hold/1 Sell[12]
- Bull: Data flywheel + partnerships (e.g., Pathos AI) drive 30%+ NRR; Bear: Dilution risk, execution on MRD reimbursement[14]

Compete by de-risking via narrow AI niches (e.g., imaging like Schrodinger); premium requires proving 40%+ CAGR and 10%+ EBITDA margins by 2028.

**Current valuation embeds ~25% CAGR to 2027 ($1.94B revenue) at 5x forward P/S with 4% EBITDA margins, a discount to Guardant/Veeva (8-12x) but premium to speculative AI-biotech (RXRX 20x+); to earn 10x EV/Rev premium, Tempus needs 35%+ growth via AI trial matching (126% NRR) and diagnostics doubling, while 15% growth risks 4x de-rating toward SDGR/TXG levels.[13][4]
- Implied: At $78 PT (~$13.5B mkt cap), ~8.5x 2026 rev / ~17x gross profit, assuming margin to 65%+
- Peers average ~7x EV/Rev (Veeva 8.3x, Guardant 12.7x, SDGR 2.6x, TXG 3.5x, RXRX ~15x est. on $75M rev)[9]

Entrants: Target 30%+ growth / 70% margins for parity; Tempus' data moat justifies slight premium if pharma deals accelerate, but high debt/equity (~2.5x est.) caps leverage. Confidence: High on metrics (Yahoo/Finbox verified Mar 2026), medium on forward growth (analyst est. range wide).

Recent Findings Supplement (March 2026)

Tempus AI's Q4 2025 Earnings Ignite Multiple Compression: Trading at 6.2x Forward EV/Revenue Despite 25% Growth Guide

Tempus AI (TEM) crushed Q4 2025 expectations with $367M revenue (83% YoY growth, 33.5% organic ex-Ambry acquisition), flipping to positive $13M adjusted EBITDA via diagnostics scale (oncology volumes +29%, ASPs to $1,640) and data licensing surge (Insights +70% YoY ex-prior warrant). This data flywheel—8M+ de-identified records powering AI models for pharma—drives $1.1B backlog and 126% NRR, but shares sold off on FY2026 guide of $1.59B revenue (25% growth) seen as deceleration from 83% FY2025. At ~$52/share (mkt cap $9.3B, EV $9.9B), TEM's TTM P/S 7.2x and EV/Rev 7.8x (GP ~$798M TTM) now discount to peers on growth-adjusted basis; forward EV/2026 rev ~6.2x bakes in margin leverage to $65M adj. EBITDA (4% margin).[1][2]
- FY2025 rev $1.3B (+83% YoY), diagnostics $956M (+112%), data/apps $316M (+31%)
- Q4 non-GAAP GP margin 66% (Diagnostics 62%, Data 75%); oncology ASP +$40 QoQ to $1,640, +$500 upside potential via FDA shifts/payer wins[2]
- Cash $760M; peers like Guardant (GH) trade 12.7x EV/TTM rev on $982M rev but slower ~30% guide[3]

Implication for Competitors/Entrants: TEM's data moat (exclusive hospital network + multimodal AI) justifies premium if 2026 data rev accelerates to 40% (as guided); new entrants need proprietary datasets to compete, as banks/generic AI can't replicate real-time oncology insights.

Analyst Targets Reflect Bull/Bear Split on Margin Ramp: Consensus $88 Implies 70% Upside, But Bears Flag Cash Burn

Post-Q4 (Feb 2026), 23 analysts rate Moderate Buy with $88 avg target (69% upside from $52), ranging $59 (Baird Outperform) to $100+ (Mizuho/Needham pre-cut); recent tweaks include MS $85→$70 (Overweight), Needham $100→$75 (Buy), BTIG $105→$90 (Buy). Bulls bank on 25%+ rev growth + data margins to 80% yielding $65M EBITDA (guide); bears (e.g., Rockflow $20-35 base) cite GAAP losses (-$245M FY2025), FCF burn, and dilution risk despite $760M cash.[4][5]
- Consensus: 8 Buy/4 Hold/1 Sell; avg $78-88 across MarketBeat/Chartmill/TIKR[4]
- Bull: 60% rev growth to $2B, 65% margins → $130/share; Bear: 35% growth, 60% margins → $40/share (AskTraders pre-earnings)[6]

Implication for Competitors/Entrants: Targets assume TEM captures 40% data growth via partnerships (e.g., AstraZeneca benchmarks met); peers like Recursion (RXRX, 15.6x EV/rev on $75M rev) must prove AI-drug hits to close valuation gap—TEM's diagnostics cashflow funds R&D moat.

TEM Discounts to Diagnostics Peers on Speed: 7.8x EV/Rev vs Guardant 12.7x, Veeva 8.3x Despite Triple-Digit FY2025 Growth

TEM's TTM EV/Rev 7.8x (P/S 7.2x) trails Guardant (12.7x EV/Rev, $982M rev) and Veeva (8.3x EV/Rev, $3.2B rev) despite 83% growth vs GH's 33%; Schrödinger (2.6x EV/Rev, $256M rev) lags on slower 23% growth. Mechanism: TEM blends high-volume diagnostics (62% margins) with 75% data margins, but acquisition integration (Ambry/Paige) caps near-term leverage vs pure-play GH.[1][3][7]
- GH: EV $12.5B / $982M rev =12.7x; Veeva: EV $25.6B / $3.2B=8.0x; SDGR: EV $0.65B / $256M=2.6x; RXRX: EV $1.2B / $75M~15x[8]
- TEM GP TTM $798M → EV/GP ~12.4x; peers: GH $633M (EV/GP 19.7x), Veeva $2.4B (10.6x)

Implication for Competitors/Entrants: To earn GH-like premium, TEM needs 2026 diagnostics ASP +$500 (mix/FDA) + data 40% growth; entrants face barrier matching TEM's 126% NRR without scale.

Forward Valuation Assumes 4% EBITDA Margin: 152x Implied, But Data Ramp Could Justify 10x+ EV/Rev Re-Rating

Consensus embeds ~$65M adj. EBITDA on $1.59B rev (guide, 4% margin) → ~152x EV/EBITDA; current 6.2x fwd EV/rev assumes steady 25% growth to profitability (2027+). Non-obvious: $1.1B backlog (growing >rev) + AI (e.g., foundation models w/AstraZeneca) could double data rev, lifting margins to 10%+ vs peers' 5-15%, supporting 10x fwd rev (like Veeva).[2]
- FY2026 rev guide $1.59B → fwd P/S ~5.9x, EV/Rev 6.2x (cash offsets debt)
- If data hits 40% (guided), EBITDA $100M+ → 99x, but scales to 20x peer avg on outperformance[9]

Implication for Competitors/Entrants: Premium requires proving data > diagnostics (75% vs 62% margins); Recursion/SDGR (high-burn AI) can't match without TEM-like clinical vol—focus on partnerships to build moat.

Recent Analyst Shifts Signal Caution Amid Volatility: Targets Cut But "Moderate Buy" Holds

Feb-Mar 2026: MS $85→$70, Needham $100→$75, Baird initiates $59 (all Buy/Outperform); H.C. Wainwright $89→$95. Consensus $78-88 (36-70% upside) vs Oct 2025 peaks $100+; bears cite dilution/execution, bulls backlog/AI.[4]
- 23 analysts: Mean $88 (+69%); dispersion high (bull $100+, bear $20-35)[10]

Implication for Competitors/Entrants: TEM's guide tempers hype, but beats validate premium potential—watch Q1 for data acceleration to force peer re-rating.

Confidence: High on financials (direct 10-K/earnings); Medium on peer multiples (Yahoo as-of 3/2026, no Q1 updates); peer rev estimated TTM. Additional Q1 peer earnings would refine.[1][3]

Professional Track Record as Founder-Operator

Eric Lefkofsky operates as a serial founder-operator who seeds high-growth tech-enabled service businesses with proprietary platforms, takes them public via IPOs (four total: InnerWorkings 2006, Echo Global Logistics 2009, Groupon 2011, Tempus AI 2024), then transitions to board/chair oversight while retaining significant equity—allowing him to capture upside from early investments but often leaving public shareholders with post-IPO value destruction due to overhyped growth that fails to sustain amid competition and execution issues. This pattern repeats: rapid scaling via salesforce expansion and tuck-in acquisitions, followed by revenue recognition scrutiny (e.g., Groupon restatements), executive churn, and sharp stock declines (Groupon -95% from IPO; InnerWorkings sold 66% below IPO price).[1][2][3]
- Founded InnerWorkings (2001, print procurement): IPO Aug 2006 at $11/share; peaked ~$18/share but restated results post-CEO Eric Belcher departure (now Tempus audit chair), material weakness in controls; sold to PE 2021 at fraction of IPO cap.[4]
- Co-founded Echo Global Logistics (2005, freight brokerage): IPO June 2009; grew via tech platform but acquired private 2021 by Jordan Co. for $2.55B (modest multiple on ~$500M revenue).[5]
- Co-founded Groupon (2008, daily deals): IPO Nov 2011 at ~$13B valuation ($20/share post-split adj.); revenue peaked 2011 then declined sharply; multiple restatements (e.g., 50% revenue cut); Mason fired 2013, Lefkofsky interim/permanent CEO 2013-2015 then Chairman until 2023.[6]
- Founded Tempus AI (2015, AI/precision medicine): IPO June 2024 at $6B; revenue $1.27B in 2025 (+83%); volatile post-IPO (+70% then shorts like Spruce Point).[7]

Implication for competitors/entrants: Aspiring operators must match Lefkofsky's VC-backed scaling speed (e.g., Lightbank funding) but avoid over-reliance on founder hype—public markets punish when unit economics erode (Groupon deals commoditized overnight).

Key Executive Hires, Backgrounds, and Departures

Lefkofsky hires from his network of prior companies/VCs, favoring operators with public-tech experience but leading to high turnover in growth phases (e.g., Groupon lost CTO Sri Viswanath 2015 amid slowdown, CFO Jason Child 2015; InnerWorkings CEO Belcher oversaw restatements). At Tempus, executives like CFO James Rogers (ex-Groupon) and COO Ryan Fukushima (ex-Lightbank) extend the pattern, with no major departures yet post-IPO but recent insider sales (e.g., Fukushima 120K shares Dec 2024).[8][9]
- Groupon: CEO Andrew Mason (co-founder, fired 2013); CFO Jason Child (ex-Amazon, departed 2015); CTO Kenneth Pelletier/SVP Eng. Brian Totty (ex-MIT/Harvard; CTO role later Sri Viswanath, resigned 2015); no prominent CMO; COO Margaret Georgiadis (ex-Google/Discover, later Pivotal CEO).[6]
- InnerWorkings: CEO Steven Zuccarini (ex-RR Donnelley); later Eric Belcher (CEO until 2018 restatements); Lefkofsky founder/board until 2012.[10]
- Echo: No specific C-suite detailed; founders Lefkofsky/Keywell on board.
- Tempus: COO Ryan Fukushima (Lightbank 2014-15, Pathos AI co-founder); CFO James Rogers (Groupon 2011-17); Chief Admin/Legal Erik Phelps (Epic Systems GC); GC Andrew Polovin (Uptake/Bartlit Beck); CTO Shane Colley (joined 2022); no CMO listed.[9][11]

Implication for competitors/entrants: Network hires accelerate ramps but risk loyalty conflicts (e.g., Pathos AI deals at Tempus)—new entrants should prioritize diverse external talent to mitigate founder-centric churn.

Insider Ownership, Lockup Schedules Post-IPO

Lefkofsky maintains founder control via high ownership (e.g., Tempus 24% Class A/60% voting as of 2025 13G), with lockups standard 180 days but early releases via price triggers/RSU sell-to-cover enabling phased liquidity without full overhang dump—though pre-IPO cashouts (Groupon: $382M via affiliates) drew scrutiny.[12][6]
- Groupon: Founders (Lefkofsky/Keywell/Mason) ~40% pre-IPO; post-IPO ~55-60% voting via Class B (150x votes/share); 180-day lockup (standard, underwriter waivers possible); Lefkofsky affiliates cashed out $300M+ pre-IPO.[6]
- InnerWorkings: Lefkofsky founder stake significant; no dual-class details.
- Tempus: Lefkofsky 42.8M Class A equiv. (24%, 59.9% voting via 100% Class B at ~15-30x votes); 180-day lockup (exceptions: 15% shares for M&A, RSU tax sales ~91/120 days post-IPO); D&O ~25% Class A/61% voting.[9]

Implication for competitors/entrants: High insider stakes align early but dual-class entrenches control—IPOs without it may attract premiums but demand broader governance.

Governance Structure and Control Concentration

Dual-class shares (Groupon: Class B 150 votes; Tempus: Class B 15-30 votes, Lefkofsky 100%) concentrate ~60% voting in Lefkofsky despite <25% economic ownership, enabling board dominance even post-IPO; qualifies as "controlled company" (Nasdaq exemptions available but Tempus declined), with Lefkofsky as observer on nom/gov committee.[13][6]
- Boards feature Lefkofsky allies (e.g., Tempus: Belcher ex-InnerWorkings CEO; Leonsis/Barris ex-Groupon/Echo); independent per Nasdaq but audit/comp/nomgov committees oversee.
- Certificate/bylaws: No cumulative voting; supermajority amendments; preferred issuance power.

Implication for competitors/entrants: Founder control aids vision but deters activists—balance with independent oversight to avoid short-seller attacks (e.g., Spruce Point on Tempus history).[3]

Reputational and Governance Red Flags/Positives

Red flags: History of value destruction (Groupon/Echo/InnerWorkings poor public returns); aggressive promotion/cashouts (Starbelly blamed for HA-LO bankruptcy; Groupon pre-IPO $382M); accounting issues (Groupon 50% revenue restatement; InnerWorkings restatements/material weakness); related-party deals (Groupon: $4.2M to Lefkofsky firms like InnerWorkings/Echo/legal by brother; Tempus: $0.8M aircraft, Pathos AI services/warrant, $5.3M dividend); Spruce Point shorts citing "promote, cash out, leave shareholders losses."[3][14]
Positives: Prolific unicorn creator (6x); philanthropy (Lefkofsky Family Foundation); Tempus revenue trajectory strong; no personal legal findings; retains skin-in-game (Groupon ~10%, Tempus 24%).[15]

Implication for competitors/entrants: Red flags amplify short risk—mitigate via clean audits, arm's-length RPTs; positives show operator resilience for VC raises. Confidence: High on facts (SEC-sourced); medium on performance causality (estimated from reports).

Medicare Coverage for Tempus Assays

Tempus xT CDx, the company's flagship 648-gene solid tumor NGS panel, secured national coverage under NCD 90.2 for advanced solid tumors (including CRC) via FDA approval and CMS transmittal, enabling automatic reimbursement at an initial ADLT rate of $4,500 (July 2024–March 2025), transitioning to private payer median thereafter; this mechanism bypasses variable LCDs by tying coverage to FDA status and patient criteria like prior systemic therapy failure.[1][2]
- xT (non-CDx LDT version) covered under MolDX LCDs (e.g., L38045) for solid tumors/hematologic malignancies in tumor-normal or tumor-only sequencing when NCD 90.2 criteria met (advanced cancer, physician-ordered, CLIA lab).[3][4]
- HRD (add-on to xT/xR) lacks specific LCD/NCD but falls under broader NGS policies; available pan-cancer, validated for ovarian via xT tumor-normal.
- xF (105-gene liquid biopsy), xE (whole exome), xR (RNA): No dedicated NCD/LCD found; potential MAC discretion under NCD 90.2 Section D for LDTs or plasma LCDs (L38043, e.g., Guardant precedent), but not explicitly listed—reimbursement varies by jurisdiction.[5]

Implications for competitors/entering space: Medicare's FDA-fast-track via NCD 90.2 gives Tempus xT CDx a reimbursement moat (ASP uplift >$1,500 vs. LDT), but LDT-heavy rivals (e.g., Caris) face patchwork LCDs; new entrants need FDA/CDx path or MolDX tech assessment to avoid denials (50%+ claim denial risk pre-coverage).[6]

Medicaid Coverage Status

Medicaid coverage for Tempus NGS assays is state-variable, with no national policy; Tempus states original Medicaid/Managed Medicaid patients typically pay $0 out-of-pocket (subject to plan rules), implying acceptance and reimbursement for key assays like xT, but tied to state fee schedules mirroring Medicare NCD 90.2 for advanced cancer NGS.[7]
- No assay-specific Medicaid LCD/NCD equivalents; follows Medicare precedents (e.g., xT via MolDX), with states like CA/FL often aligning for oncology NGS.
- Sponsored NGS programs (e.g., Lilly-Tempus for advanced cancers) bridge gaps for uninsured/Medicaid.

Implications: Medicaid's 80M+ enrollees offer volume, but low rates (~50-70% Medicare) pressure margins; competitors succeed via state-specific advocacy (e.g., Guardant), while entrants risk non-coverage in budget-constrained states without pharma sponsorships.

Commercial Payer Coverage Policies

Tempus bills all commercial plans, with expanding in-network status (e.g., Cigna for NGS, UHC expanded CGP coverage including xF); xT CDx ASP ~$2,900 (LDT) migrating to $4,500, xF poised for uplift post-FDA; policies emphasize NCCN-aligned utility in advanced solids.[8][9][10]
- Cigna Policy 0520 excludes some Tempus add-ons (p-MSI, p-Prostate) as unproven, but covers core NGS; Humana notes xT/xR split for DNA/RNA.[11][12]
- 2025-2026 tailwinds: xF commercial coverage/FDA to boost blended ASP >$2,200.

Implications: Payers follow Medicare (e.g., UHC post-NCD expansions), favoring FDA tests; Tempus' 75%+ collection rate reflects strong prior auth, but non-covered add-ons (e.g., Cigna exclusions) cap upside—rivals like Foundation leverage Roche scale for broader policies.

HIPAA and Data Privacy Risks in De-Identified Data Licensing

Tempus licenses >8M de-identified multimodal records (HIPAA 45 CFR 164.514-compliant) to 19/20 top pharmas ($2B+ contracts), claiming removal of 18 identifiers enables unrestricted research use; however, 2026 class actions (IL N.D.) allege GIPA violations post-Ambry acquisition, arguing "de-identified" genetic data remains re-identifiable via linkages, lacking consent for pharma sharing/AI training.[13][14][15]
- No FTC scrutiny/settlements found for Tempus; general FTC health breach warnings apply (e.g., tracking tech), but focus on hashing ≠ de-ID.[16]

Implications: HIPAA safe harbor protects if truly de-ID'd, but genomic re-ID risks (e.g., 99% via relatives) invite state suits; peers (Flatiron/Foundation) use HIPAA-anonymized clinico-genomic DBs without major privacy suits, navigating via firewalls/consents—entrants must audit re-ID risks or face 20-50% valuation hits from litigation.

State Health Data Privacy Laws (e.g., WA My Health My Data Act)

Tempus' Consumer Health Data Policy explicitly addresses MHMDA (effective 2024), granting WA "consumers" rights to access/delete/share non-HIPAA health data (e.g., consumer-facing apps); broader compliance via notices for CCPA/CPA, but GIPA suits highlight gaps in genetic consent for acquired data.[17][18]
- No MHMDA-specific enforcement vs. Tempus; policy appeals to privacy@tempus.com.

Implications: MHMDA's broad "consumer health data" (no provider nexus needed) exposes licensing if sold to WA pharmas; peers comply via opt-out notices—new models need granular consents to avoid AG fines ($7,500/violation).

Peer Navigation of Regulatory Exposure

Flatiron/Foundation (Roche) license HIPAA-de-ID'd clinico-genomic data (e.g., 20K+ patient DB) via firewalls, avoiding privacy suits through research-only covenants and no re-ID claims; resolved patent/false ad disputes (Guardant/Carisi) via settlements ($25M+ royalties), focusing on FDA/CDx for reimbursement moat.[19][20]
- No major data privacy FTC/state suits; emphasize "anonymized" in partnerships.

Implications: Peers' Roche backing enables scale/compliance; Tempus differentiates via AI/multimodal but risks via aggressive licensing—entrants should hybrid (HIPAA + consents) to mirror Flatiron's low-litigation path.

Regulatory Risk Matrix

Overall: Reimbursement strong for xT (ASP trajectory >$2,200), privacy litigation rising (GIPA focus); peers' acquisition strategies + FDA emphasis reduce exposure—additional state audits recommended for confidence. Data current as of March 2026 searches; LCDs evolve quarterly.[21]

Recent Findings Supplement (March 2026)

Medicare Coverage Landscape

Tempus xT CDx (0473U), its FDA-cleared 648-gene NGS solid tumor panel, gained explicit recognition in updated 2026 payer policies aligning with CMS NCD 90.2 for NGS-based tumor profiling, enabling higher reimbursement (~$4,500 vs. ~$2,900 for LDT version) via ADLT migration; this drove oncology ASP to $1,600 in Q3 2025 (up $20 QoQ) with ~30% xT volume shifted, per Tempus Q3 earnings.[1][2]
- Q4 2025 oncology ASP rose to $1,640; management projects $2,200+ long-term via full xT/xF/xR FDA approvals and payer negotiations.[3]
- No new LCD/NCD post-9/9/2025; MolDX reviews ongoing for MRD (xM CRC tumor-naïve) and xF liquid biopsy PMA (Q4 2025 submission planned), constraining sales to pilot volumes until H2 2025 coverage.[4]
Implications for competitors: Without FDA-cleared assays like xT CDx, rivals (e.g., FoundationOne) face LDT pricing caps; Tempus's multi-assay menu positions it for NCD 90.2 parity, but delays in MolDX could cede MRD share to Personalis (new breast/lung coverage Q4 2025-Q1 2026).[5]

Commercial Payer Coverage Policies

Payers like UnitedHealthcare (effective 1/1/2026) and Providence explicitly list Tempus xT CDx/xR/nP in oncology/pharmacogenomic policies, covering under companion diagnostics or medically necessary NGS when guidelines (e.g., NCCN/ESMO) met; Blueshield CA (10/1/2025) notes xT CDx FDA clearance but deems broad profiling investigational absent biomarkers.[6][2]
- Medica/Dean (1/1/2026) covers algorithmic assays like Tempus p-MSI/p-Prostate (0512U/0513U) for prostate; xG hereditary panel listed but investigational without criteria.[7]
- No Medicaid-specific updates; general PGx panels (e.g., nP 0419U) require prior failure of ≥1 med per CMS MolDX.
Implications for competitors: Peers like Guardant/CarIs face similar "guideline supersedes policy" scrutiny (e.g., DrOracle.ai appeal); Tempus's EHR integration accelerates prior auth, but payer restrictions on large panels cap volumes absent FDA.

Key Assay-Specific Developments

Tempus xR IVD gained FDA 510(k) (9/22/2025) for RNA NGS detecting rearrangements in 2 genes (solid tumors), positioning for life sciences/pharma use but clinical reimbursement tied to NCD 90.2; xF liquid biopsy PMA submission end-2025 targets ADLT uplift.[8]
- nP pharmacogenomic (0419U) appears in policies (e.g., Excellus 2/19/2026, Providence 1/27/2026) for personalized tx but investigational broadly; Pixel/ECG (AFib/LowEF) cleared but no dedicated codes/reimbursement yet (~$128 CMS for similar cardiac AI).[9]
- MRD limited (low-single-digit oncology volume); Personalis partnership expands to CRC but gated on MolDX.[1]
Implications for competitors: FDA-cleared xR/xT edges non-IVD peers; entering space requires MolDX dossiers (e.g., Personalis 3 indications pending), with Tempus's data moat aiding evidence generation.

HIPAA and Data Privacy Regulatory Risks

Tempus faces novel class action (Nash v. Tempus, N.D. Ill., filed ~2/14/2026) alleging GIPA violations via Ambry Genetics acquisition: compelled disclosure of Illinois patients' genetic data (without consent) for AI training/sharing with pharma, despite "de-identified" claims; seeks damages for ~thousands affected.[10]
- No FTC scrutiny/actions post-9/9/2025; Tempus RFI (2/23/2026) urges HHS tie AI reimbursement to FDA/value, notes coding gaps.[11]
- No My Health My Data Act (WA/NV/CT) complaints/enforcement vs. Tempus; general state AG suits (e.g., generics antitrust) unrelated.
Implications for competitors: Peers (e.g., Foundation) navigated via consent/de-ID audits; Tempus's 8M+ records amplify exposure—resolution via motion could set precedent, but appeals risk multi-state class expansion.

Peer Navigation of Regulatory Exposure

Personalis secured Medicare MRD coverage (breast Q4 2025, lung Q1 2026) via dossiers, targeting 170% clinical volume growth 2026 despite biopharma dip; Guardant/CarIs maintain via FDA (e.g., Guardant360 TissueNext 0334U listed UHC).[12]
- FoundationOne CDx remains benchmark in NCD 90.2; all peers bundle data licensing (e.g., Personalis-Tempus distribution).
Implications for competitors: Data peers emphasize FDA/MolDX pre-coverage volume build; Tempus mirrors but lawsuit differentiates—mitigate via Ambry consents, as peers did post-acquisitions.

Risk Matrix

Confidence: High on reimbursement (earnings/policies); Medium on privacy (single suit, early stage). Additional MolDX dockets/FTC FOIAs would strengthen.

Total Addressable Market for Pharma RWD Licensing

Tempus leverages its multimodal oncology dataset—combining de-identified clinical notes, genomic sequencing from 300,000+ patients, and imaging—to enable pharma partners to train foundation models that identify novel drug targets 3-5x faster than traditional methods, as seen in its $200 million AstraZeneca/Pathos deal where real-time sales-linked repayment reduces lender risk compared to banks' collateral-heavy loans.[1][2]
- Global RWD market valued at $2.34 billion in 2026, projected to reach $4.21 billion by 2030 (15.8% CAGR), driven by AI analytics and regulatory acceptance of RWE for approvals[3]
- Pharma end-users dominate (~60% share), using RWD for trial design, patient matching, and post-market surveillance; oncology RWD subsets growing fastest at 16-18% CAGR[4]
- Related RWE solutions market at $5.42 billion in 2025, expanding to $10.8 billion by 2030 (14.8% CAGR), with AI-powered subsets (e.g., Tempus-style models) accelerating due to FDA/EMA guidelines[5]

Implications for competitors: New entrants must build proprietary multimodal datasets (clinical + genomic + imaging) exceeding 1 million records for defensible moats, as commoditized claims/EHR data alone yields inferior AI models; partner with sequencers like Illumina early to capture longitudinal outcomes.

Tempus's Pharma Partnerships and Strategic Edge

Tempus's platform aggregates real-time multimodal data (8 million+ de-identified records delivered to pharma) via 700+ integrations across 5,000+ sites, enabling "just-in-time" trial matching where AI stratifies patients by molecular/clinical profiles in hours vs. months, powering 19/20 top pharmas and yielding >$1.1 billion TCV (up from $940 million in 2024).[6][7]
- Key deals: $200 million (2025) data licensing/modeling with AstraZeneca/Pathos for world's largest oncology foundation model; expansions with GSK ($70 million upfront for 3 years), Pfizer, BMS[1][8]
- 70+ new 2025 agreements (AstraZeneca, GSK, Pfizer, Novartis, Merck, Lilly); 126% net revenue retention reflects expansions (e.g., Insights licensing up 69%)[7]
- TCV breakdown: ~$350 million for 2026 visibility; includes $300 million opt-ins; Data/Apps revenue hit $316 million in 2025 (31% YoY)[9]

Implications for competitors: Oncology specialists like Tempus hold data moats from sequencing flywheels (31,000+ annual samples), forcing generalists to acquire (e.g., Roche's $1.9 billion Flatiron buy) or partner; mid-sized pharmas entering via Tempus-like platforms gain 2-3x faster target ID but risk vendor lock-in without multi-sourcing.

Contract Structures: Subscriptions vs. Milestones

Tempus structures deals as multi-year data licensing with upfront fees + usage-based milestones tied to model milestones (e.g., $200 million AstraZeneca/Pathos: licensing + development fees), blending subscription-like access to longitudinal datasets with performance triggers that align incentives and auto-renew via opt-ins, yielding 126% retention vs. pure milestone risks.[1]
- Tempus/GSK: $70 million upfront for 3-year access + task orders for screening/services[8]
- IQVIA: "Data as a Service" subscriptions for harmonized RWD (EHR/claims), milestone-heavy for custom RWE studies; no specific sizes disclosed but powers 90% global pharma tracking[10]
- Flatiron (Roche-owned): Licensing to pharmas pre-acquisition; now internal + partnerships (e.g., Sanofi trials); structures undisclosed but EHR-derived RWD favors subscriptions[11]

Implications for competitors: Hybrid models (upfront 30-50% + milestones/opt-ins) de-risk for cash-strapped biotechs while ensuring vendor revenue durability; pure subscriptions commoditize data, eroding pricing power amid AI commoditization.

Competitive Dynamics Among Key Players

IQVIA dominates with 25%+ U.S. RWE share via 1.2 billion patient records (claims/EHR), powering analytics platforms where AI harmonizes multi-source data for 90% global pharma sales tracking, outpacing oncology-focused rivals through scale but lagging Tempus/Flatiron in multimodal depth.[12]
- IQVIA/Flatiron/Tempus top-5 (85% U.S. RWE share combined); Tempus leads oncology AI (>$1.1B TCV, 70+ deals); Flatiron (Roche) excels EHR curation (5M+ records)[13]
- Veeva/Medidata: Platform plays (Vault CTMS/Rave EDC); Acorn AI for commercial insights, not pure RWD licensing; compete via integrations (e.g., Medidata's 36,000 trials)[14]
- Tempus differentiation: Genomic flywheel (80,000+ Algos ordered) enables superior oncology models vs. IQVIA's claims-heavy data[15]

Implications for competitors: Scale players (IQVIA) win breadth; specialists (Tempus oncology) capture premiums via vertical moats; platforms (Veeva/Medidata) bundle RWD into SaaS, pressuring pure licensors to API-integrate or face disintermediation.

Revenue Durability Amid Budget Cycles and AI In-Housing

Pharma R&D budgets rose 8-10% in 2025 ($200B+ global), sustaining RWD demand despite cycles, as AI shifts from experimentation (17% measurable R&D ROI) to core (50% expect 2026 value), favoring durable licensing over one-offs; in-housing limited by data moats (e.g., Tempus's 126% retention proves stickiness).[16]
- 77% pharma uses RWD; 54% AI-integrated; value-based care mandates ongoing RWE for pricing/reimbursement[17]
- Trends: Quality > quantity RWD; AI precision (e.g., Tempus models) locks in multi-year deals; regulatory scrutiny favors verified providers[18]
- Durability: TCV models (Tempus $1.1B) buffer cycles; 99% plan trial inclusivity via RWD/AI[19]

Implications for competitors: Revenue stable via subscriptions/opt-ins (40%+ growth projected); counter in-housing by federated learning APIs allowing pharma AI on vendor data without transfer, preserving moats while enabling "AI factories."[20]

Recent Findings Supplement (March 2026)

Tempus's Surging Data Licensing Momentum

Tempus AI solidified its position as the leading AI-enabled RWD provider to pharma by announcing a record Total Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025—up from $940 million at end-2024—fueled by 70+ new data agreements with majors like AstraZeneca, GSK, BMS, Pfizer, Novartis, Merck, AbbVie, Daiichi Sankyo, Eli Lilly, and Boehringer Ingelheim; this reflects pharma's shift to Tempus's multimodal (genomic + clinical) dataset for biomarker discovery, where real-time longitudinal linkages enable causal AI models that predict resistance mechanisms banks of traditional data can't match, turning raw RWD into proprietary drug hypotheses.[1][2]
- Data & apps revenue hit ~$316 million in 2025 (31% YoY growth), with Insights (licensing) up 38%; net revenue retention at 126% shows expansions outpacing churn.[3]
- March 3, 2026: Expanded multi-year Merck deal grants access to Lens platform + GPU-powered Workspaces for oncology biomarker ID and combo testing, initially oncology but expandable—positioning Tempus as Merck's core AI data partner post-Keytruda.[4]
Implication for competitors: Tempus's scale (200+ biopharma clients) creates a flywheel where more data refines AI, locking in renewals; Flatiron/IQVIA must accelerate multimodal oncology linkages or risk commoditization.

Medidata's AI Study Build Expansion in Oncology Trials

Medidata (Dassault Systèmes) expanded its 14-year partnership with Menarini Group/Stemline Therapeutics on March 9, 2026, deploying AI Study Build to auto-generate protocols from vast historical clinical datasets, slashing trial startup from months to days by matching patient cohorts to protocols via NLP on EDC/eCOA data—enabling Stemline's first fully in-house oncology study while retaining Medidata's platform lock-in.[5]
- Builds on Medidata Rave EDC + eCOA; AI leverages "vast clinical data set" for independence in global oncology pipeline acceleration.[6]
- Recent CRIO integration eliminates double-entry across 2,500 sites, feeding cleaner RWD into AI workflows.[7]
Implication for competitors: Veeva/Medidata's AI-native trial design moats trial ops; IQVIA must integrate its RWD faster into similar tools, or lose to platforms owning the data-to-protocol pipe.

Flatiron's AI-Extracted RWD Datasets Go Global

Flatiron (Roche) launched AI-powered Panoramic prostate cancer datasets in UK/Germany (Feb 2026), using VALID Framework (F1 scores matching human abstractors across 14 cancers) to extract progression/biomarker data from EHRs at scale—expanding its 5M+ patient repository (1.5B data points) beyond US, enabling cross-border RWE for post-market Phase IV trials.[8]
- Paradigm acquired Flatiron's clinical research arm (Dec 2025) for embedded Phase IV in routine care, generating RWD for 23 NCI sites.[9]
- Hematology datasets grew 6x to 505K patients (Oct 2025), with "digital twin" OS prediction via LLM-extracted variables.[10]
Implication for competitors: Flatiron's oncology RWD depth forces Tempus/IQVIA to match AI validation rigor; new entrants need EHR partnerships to compete in global expansion.

IQVIA-Veeva Tie-Ups Bolster RWD Interoperability

IQVIA renewed RWD pact with Institut Curie (Nov 2025, 3 years) for cancer insights, while Oct 2025 Veeva partnership enables IQVIA OneKey data flow into Vault/CRM via TPAs (issued in 10 days)—unlocking master data management for HCP linking without rebuilds, as pharma shifts to hybrid data ecosystems.[11][12]
- Sep 2025: IQVIA-Veeva decentralize trials via CRO + Vault tech integration.[13]
Implication for competitors: Interop wins (e.g., IQVIA's 1.2B records) favor incumbents; Tempus must API its Lens platform broadly or cede to ecosystem plays.

RWD/RWE TAM Estimates Converge on $3-6B in 2025, Explosive Growth Ahead

Analyst consensus pegs global RWE solutions TAM at $3.0-3.3B in 2025 (pharma ~45% share), growing to $6-11B by 2034-35 at 8-16% CAGR—driven by AI curation of EHR/claims for regulatory/payer use, with pharma prioritizing oncology/cardio; no pharma-specific licensing TAM disclosed, but Tempus's $1.1B TCV implies 20-30% capture in data subset.[14][15][16]
- RWD market: $1.9-3.3B (2025) to $6-7B (2034), AI-powered at 14.8% CAGR.[17]
- US RWE: $1.1B (2025) to $4.1B (2034), IQVIA/Flatiron ~85% share.[18]
Implication for competitors: Fragmented $3B+ TAM rewards AI scale; in-housing trends (pharma building AI on licensed data) sustain licensing if providers like Tempus offer GPU compute moats.

Revenue Durability Amid AI In-Housing and Budget Pressures

Pharma AI budgets split: quick wins (data ops/commercial, 47-49% proving value) vs. long-cycle R&D (17-30% now, 42-45% in 2026), with RWD fueling clinical planning/recruitment; in-housing rises (e.g., AstraZeneca's Modella AI), but hybrid prevails—licensing RWD as "fuel" persists as pharmas lack multimodal depth/Tempus-scale linkages, buffering budget cycles via NRR like Tempus's 126%.[19]
- No direct in-housing threats to licensing; pharma invests $6-9B in RWD (2024 est.), with 45-60% programs yielding value (15-35% enrollment cuts).[20]
Implication for competitors: Durable if AI+RWD combos (e.g., Tempus Lens) exceed in-house baselines; monitor pharma M&A (licensing $232B in 2025) for data asset grabs.[21]

Data Moat Vulnerability to Roche Replication

Tempus AI's claimed data moat—built from 9M+ patient records with paired clinical-molecular data—is replicable by Roche, which owns Foundation Medicine (genomic sequencing) and Flatiron Health (oncology EMR data); Roche could integrate these via internal APIs like Flatiron's OncoEMR, which already embeds Tempus tests, eroding Tempus's exclusivity as pharma clients shift to cheaper in-house alternatives without licensing fees.[1][2][3]
- Roche acquired Flatiron (EMR data) and Foundation (genomics) for $4.3B combined in 2018, creating a vertically integrated dataset mirroring Tempus's multimodal approach.[4]
- Tempus integrates with Flatiron's OncoEMR for ordering/results, signaling interoperability that lets Roche aggregate Tempus data indirectly while building its own moat.[3]
- Competitors like Guardant (liquid biopsy) and Caris lack full clinical-genomic pairing, but Roche's scale (thousands of oncologists) enables rapid replication, with FMI seeing declining volumes as Tempus poaches share.[5]

Implications for Competitors/Entrants: Roche's combo already covers Tempus's core (sequencing + EMR), so new entrants must partner (risking data commoditization) or acquire scale via M&A; bears materialize if Roche launches a unified AI platform by 2027, capping Tempus data licensing at 30-38% YoY growth vs. management's 25%+ forever assumption.[6]

Customer Concentration in Pharma Licensing

Tempus derives ~25% of revenue ($316M in 2025) from Data & Applications, heavily concentrated in top pharma like AstraZeneca (11-12% of receivables, $200M deal), GSK ($70M), Pfizer; a single client pause (e.g., AZ/Pathos scrutiny in lawsuits) could slash 20-30% of this high-margin (74%) segment, as contracts include non-binding opt-ins and related-party risks flagged in SEC filings.[7][8]
- Top 10 customers ~24% of ARR; 19/20 largest pharmas license data, but AZ/Pathos deals (key to $1.1B TCV) face lawsuit claims of overstatement/round-tripping.[9][10]
- NRR 126% hides dependency: Insights grew 38-69% but excludes one-time warrants; Spruce Point notes weakening core ops masked by deals.[11]
- 70+ new 2025 deals, but biopharma R&D cuts (e.g., post-2025 slowdown) could trigger renegotiations.[12]

Implications for Competitors/Entrants: Concentration >20% exposes to client loss (e.g., if AZ builds internal via Pathos); materialize via 10-15% revenue miss if 2-3 pharmas cut spend amid trial failures, forcing diagnostics reliance (lower margins).

Lefkofsky's Founder Track Record

Eric Lefkofsky, Tempus CEO, cashed out $300M+ pre-IPO from Groupon (IPO $13B valuation, now <5%, down 95% post-IPO) and led InnerWorkings (restated financials, acquired at loss); Spruce Point flags pattern of "promoting disruptive tech, cashing out early, leaving shareholders losses," raising execution risk in Tempus's AI hype (only 2% revenue AI-derived).[13][4]
- 6 unicorns (InnerWorkings, Echo, Mediaocean, Groupon, Tempus, Pathos), but public ones cratered: Groupon SEC probes/accounting issues; InnerWorkings -92% post-report.[11]
- Tempus lawsuits echo: overstated AI/partnership revenue (AZ/Pathos), aggressive Ambry billing.[10]
- Post-IPO, stock volatile (19% drop on Spruce May 2025 report).[8]

Implications for Competitors/Entrants: Serial promoter risk means governance overhang; bears if Q1 2026 miss triggers restatements/lawsuits, eroding trust like Groupon.

High Cash Burn and Short Runway

2025 op cash burn $218M (FCF -$239M), net loss $245M despite $760M cash; acquisitions (Ambry, Paige) + AI infra spike investing CF to -$1.28B TTM, with debt covenants tied to revenue ($594M min 2025)—violation risks dilution if growth slows.[14][15]
- Q1 2025 burn >$100M; runway ~33 months at current rate, but legal ($10sM) + SBC ($200M 2026 guide) erode buffer.[10]
- Adj EBITDA -$7.4M 2025 (Q4 +$12.9M), guides $65M 2026 but misses "slightly positive" 2025 whisper.[16]
- No LT debt listed, but term loans ($460M+ post-Ambry) at high rates.[17]

Implications for Competitors/Entrants: Burn funds growth but covenants bind; materialize on reimbursement delay/guidance cut, forcing equity raise at discount.

Dilution from SBC and Offerings

SBC $534M (2024), Q4 2025 $48.7M alone (dilutes EPS); RSU settlements (13M+ shares post-IPO), convertible notes ($750M, cap price $111/share but dilutive on convert), secondary resale (1.27M shares); 2026 SBC guide $200M signals ongoing pressure.[18][19]
- Notes reduce dilution via capped calls, but conversion yields 15.7M shares max.[20]
- Prospectus: 22M ISO pool; post-IPO RSU net settlements dilute further.[21]

Implications for Competitors/Entrants: SBC >20% revenue dilutes insiders minimally but crushes EPS; bears if stock <conv price, triggering 10-15% share float increase.

Reimbursement and Payer Risks

No direct denials found, but aggressive Ambry billing flagged in lawsuits (unsustainable scrutiny); payer pushback looms on NGS/MRD (e.g., xT-CDx $4.5K Medicare vs. LDT $2.9K, but MRD constrained pre-reimbursement); SEC notes reliance on reimbursement growth.[8][22]
- ASP oncology +$60 to $1,590 Q1 2025 via xT-CDx migration (40% target), but hereditary ASP $770 moderates.[23]
- MRD volume capped until H2 2025 codes; general NGS headwinds (e.g., NeoGenomics).[24]

Implications for Competitors/Entrants: Diagnostics (75% rev) vulnerable; materialize on CMS cuts, dropping ASP 10-20%.

Overvalued at Optimistic Assumptions

7.5x P/S (vs. peers 5.3x) prices 30%+ growth/no profits thru 2028; analysts cut targets (Stifel $60, JPM $60) on "clouded visibility," Spruce 50-60% downside; DCF sensitive to margins (15% FCF unproven).[25][26]
- $1.3B 2025 rev (83% YoY) but GAAP losses; guides $1.59B/$65M EBITDA 2026 conservative?[16]
- Spruce: core genomics/data weak despite deals; stock -19% post-report.[13]

Implications for Competitors/Entrants: Premium assumes flawless execution; bears on 20% growth/negative EBITDA (e.g., litigation), compressing to 4x P/S ($30-40/share). Confidence: High on financials/lawsuits (SEC/earnings), medium on moat/reimbursement (inferential).

Recent Findings Supplement (March 2026)

Data Moat Defensibility Amid Roche Competition

Roche's Flatiron Health (real-world oncology EHR data from >5M patients) and Foundation Medicine (800K+ tumor genomic profiles) remain potent competitors, but no post-Sep 2025 evidence shows Roche replicating Tempus' multimodal (genomic + clinical + imaging) patient-linked dataset at scale; Tempus' acquisitions like Paige AI (Aug 2025, $81M for 7M pathology slides) and Ambry Genetics (early 2025) have instead widened its lead to 9M+ records, creating a flywheel where diagnostics feed proprietary data for pharma licensing—yet Roche's integrated ecosystem could erode this if it accelerates AI cross-pollination.[1][2][3]
- Tempus claims 60x larger paired clinico-genomic dataset vs. public benchmarks; Roche's assets are strong in silos (Flatiron EMRs, Foundation NGS) but lack Tempus' full integration.[4]
- Partnerships like AstraZeneca ($200M multimodal model, Apr 2025) validate moat, but Roche's internal use limits external threat visibility.[5]
For entrants, Roche's scale means data moats alone won't suffice—must pair with FDA-cleared AI (e.g., Tempus' xR IVD, Sep 2025) and pharma deals; replication risk materializes if Roche launches open-platform equivalents by 2027.

Reimbursement Delays Capping MRD and Sequencing Growth

Tempus continues gating MRD volumes (only small sales force active) pending MolDX reimbursement decisions, with Q4 2025 CRC assay in "back-and-forth" and tumor-naive NSCLC submission slated for 2026—despite 56% QoQ MRD growth to 4,700 tests, this self-imposed limit underscores payer hurdles persisting into 2026, as blended NGS reimbursement ($1,590 oncology, up from $1,500) lags peers and ADLT/FDA migrations drag.[6][7][3]
- Oncology NGS payment rate ~55% (2022-23 data); MRD lacks broad coverage, forcing disciplined rollout vs. full commercialization.[8]
- Q3 gross margins improved modestly but ASP lags signal no major payer wins yet; FY2025 diagnostics drove 111% growth but reimbursement is key margin lever.[9]
Competitors face same barriers, but delays materialize if MolDX denies CRC/NSCLC (H1 2026), capping diagnostics at <25% of $1.59B 2026 guide.

Pharma Licensing Revenue Concentration Risks

Data & Services (30.9% FY2025 growth to $316M) relies heavily on large pharma deals (e.g., AstraZeneca $220M min. spend, GSK $180M, Pathos related-party $41.7M in 9M), with Insights licensing up 38% but no disclosure of top-customer %—echoing partner Personalis' explicit "customer concentration" warnings, where enterprise deals (Natera, VA) comprise ~25% revenue; Tempus' $1.1B TCV includes 70+ pharmas but vulnerability rises if big contracts renegotiate amid 2028 patent cliffs.[10][8]
- Net retention 126% shows stickiness, but 49% TCV due next 12 months heightens renewal risk.[3]
- No single >10% flagged, but pharma-heavy mix (~Insights 69% Q4 growth ex-warrant) ties fortunes to R&D budgets.[3]
New players need diversified small/mid-pharma to compete; bear case if 2-3 majors cut (e.g., post-Keytruda), slashing 20-30% data revenue.

Elevated Cash Burn and Dilution Pressures Despite Cash Buffer

FY2025 operating cash burn hit $218M (up from prior), with net loss $245M driven by $136M stock comp/payroll taxes; Q4 adj. EBITDA turned +$12.9M but GAAP losses persist amid acquisitions (Paige, Ambry)—$760M cash provides ~2.8-year runway at current burn, but $343M ESOP shelf (Feb 2026) and $500M ATM remainder signal dilution ahead, compounded by insiders selling 596K shares (~$37.5M, last 3M) while owning 26%.[3][8][11]
- Debt/equity 252% ($1.2B debt vs. $491M equity); convertible notes ($728M net) add conversion overhang (~9.3M shares).[3]
- FY op cash flow -17% of revenue; 2026 $65M adj. EBITDA guide assumes discipline, but SBC unrecognized $297M over 2.5yrs pressures GAAP.[8]
Runway erodes if growth misses; dilution hits if ESOP/ATM taps amid volatility (beta 5.22).

Lefkofsky Track Record and Governance Scrutiny

Founder-CEO Eric Lefkofsky's Groupon baggage (post-IPO restatements, suits, control issues) lingers as "cleanest bear case," with Class B super-voting (30x) ensuring control; recent Spruce Point short (May 2025, alleging misleading AI revenue) sparked suits (dropped Nov 2025), but Feb 2026 GIPA class action over Ambry data transfer without consent revives privacy/governance risks tied to his Pathos ties ($41M related revenue).[2][12][13]
- Insider sales (e.g., Lefkofsky 166K shares Jan 2026) fuel optics amid $10B+ mkt cap.[14]
- No new Groupon-specific critiques post-Sep, but control + related-party deals invite SEC scrutiny.
Bear materializes on adverse GIPA ruling or Pathos unwind, eroding trust.

Valuation Pricing Optimistic 25%+ Growth Amid Execution Risks

At ~8x 2026E sales ($1.59B guide), TEM embeds 25% growth and $65M adj. EBITDA (~4% margin)—rich vs. peers (oncology diagnostics ~5x) given GAAP losses, burn, and no profitability inflection; post-Q4 stock -7.5% despite beat signals skepticism on dilution/ESOP, with analysts trimming targets (Stifel $60 from $85, Piper $80).[15][3]
- Consensus PT $87 (60% upside from ~$52), but DCF varies wildly (undervalued $138 vs. overvalued models); P/S 7.5x trails 2025 peak but premiums unproven moat.[16]
Bear unfolds if 2026 misses (e.g., reimbursement stalls), compressing to 4-5x on peers.